ARTV

Artiva Biotherapeutics, Inc.

Biological Products, (No Diagnostic Substances) · SIC 2836CIK 1817241Held by 2 tracked managersEDGAR filings ↗10-K/10-Q ↗

SHARE:X LINKEDIN EMAIL

Revenue FY2025

$0.0M

Net Income FY2025

$(84.0M)

EPS (Basic, as reported)

$-3.43

Net Margin FY2025

—

ROE FY2025

-76.3%

Total Equity

$110.0M

Shares Out

49M

Business description

Artiva Biotherapeutics, Inc. — Biological Products, (No Diagnostic Substances). Figures are as reported in each year's original 10-K via SEC EDGAR XBRL company facts (FY2023–FY2025; structured XBRL data begins around 2008). Market-price metrics are not part of EDGAR data.

Annual (fiscal years, as reported)USD millions

default rows · click any row to chart itRevenue: 33 → 0

Fiscal yearFY2023⚑FY2024⚑FY2025

Revenue3300

Research & development(50)(50)(70)

General & administrative(14)(17)(20)

Total operating expenses(64)(68)(90)

Operating income(31)(67)(90)

Other income (expense), net226

Pre-tax income(29)(65)—

Income tax expense000

Net income(29)(65)(84)

EPS — basic($35.78)($5.81)($3.43)

EPS — diluted($35.78)($5.81)($3.43)

Shares outstanding — basic (M)11124

Shares outstanding — diluted (M)11124

⚑ Weighted-average shares changed ×11.00 between FY2023 and FY2024 — likely a stock split. Per-share figures on either side are as reported and not adjusted.
⚑ Weighted-average shares changed ×2.18 between FY2024 and FY2025 — likely a stock split. Per-share figures on either side are as reported and not adjusted.

Source: SEC EDGAR XBRL company facts — figures as reported in each period's original filing (structured data begins ~2008). EPS and other per-share figures are as reported and are not adjusted for later stock splits; a ⚑ marks a period where the reported share count changed by a large factor. Dollar figures in millions unless per-share. Line items a company never reports are omitted. Where a filer switched XBRL concepts, the successor concept is used and definitions can differ slightly (e.g. cash may include restricted cash; banks' revenue is net of interest expense; cost of revenue may exclude D&A; net income may be the amount available to common stockholders; debt issued/repaid may be net of issuance costs or include finance-lease obligations — each only where the original concept stopped being reported). Click a period header to open that period's source filing on EDGAR.